Advandx, based in Woburn, MA, is a leading provider of cutting-edge infectious disease molecular diagnostics that aim to improve patient care. Their innovative approaches include highly multiplexed syndromic molecular panels, next-generation sequencing, smart bioinformatics, and artificial intelligence to address the global threat of antimicrobial resistance (AMR). With a focus on precision medicine, Advandx offers rapid molecular diagnostic products and services that guide antibiotic therapy selection, optimize treatment for drug-resistant infections, improve antibiotic stewardship, and reduce the spread of multidrug-resistant microorganisms (MDROs).
OpGen, along with its subsidiaries Curetis and Ares Genetics, is dedicated to developing and commercializing molecular microbiology solutions that provide clinicians with rapid and actionable information about life-threatening infections, ultimately improving patient outcomes. Their product portfolio includes the Unyvero System and the ARES Technology Platform, which utilize next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for antibiotic response prediction. By leveraging cutting-edge molecular microbiology, OpGen and its subsidiaries contribute to the fight against antimicrobial resistance and the advancement of patient care.
Generated from the website